Physician profile
Ankush Gulati
NPI 1265445654
$40,883.16
in general payments reported to CMS, 2019-2025
28 companies · $6,826 in 2025
The $6,826 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $116 · 2021: $918 · 2022: $3,268 · 2023: $19K · 2024: $11K · 2025: $6,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $5,892 · Travel and Lodging: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,190.00 |
| Food and Beverage | $5,891.84 |
| Travel and Lodging | $370.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29,847.65 | 2020-2025 | Farxiga, Breztri |
| Akebia Therapeutics INC | $5,284.05 | 2021-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $622.56 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $553.95 | 2023-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $551.84 | 2020-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $506.07 | 2021-2025 | Acthar, Terlivaz |
| Novo Nordisk INC | $500.48 | 2021-2025 | Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $460.07 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $389.55 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.53 | 2021-2025 | Jardiance |
| Horizon Therapeutics Plc | $264.58 | 2020-2023 | Krystexxa |
| Amgen INC. | $263.99 | 2021-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $208.77 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $182.66 | 2021-2025 | Jynarque |
| Vifor Pharma, INC. | $174.94 | 2019-2023 | Veltassa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $108.46 | 2021-2024 | Velphoro |
| Ardelyx, INC. | $102.64 | 2023-2025 | Ibsrela |
| Scpharmaceuticals INC. | $97.37 | 2024-2025 | |
| Boston Scientific Corporation | $90.12 | 2019 | |
| Lilly USA, LLC | $88.33 | 2023-2025 | Jardiance |
| Quanta Dialysis Technologies INC | $76.70 | 2021 | |
| Glaxosmithkline, LLC. | $74.18 | 2021-2022 | |
| Daiichi Sankyo INC. | $56.66 | 2021-2025 | Injectafer |
| Alexion Pharmaceuticals, INC. | $45.01 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $29.29 | 2025 | |
| Vantive US Healthcare LLC | $18.44 | 2025 | Renal - Pd |
| Coala Life INC | $16.27 | 2023 | Coala Heart Monitor |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankush Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.